Novo Nordisk China

Novo Nordisk's products were introduced to the Chinese market as early as the 1960s. In 1994 Novo Nordisk decided to invest in China by setting up Novo Nordisk (Tianjin) Biotechnology Co., Ltd., which was later renamed Novo Nordisk (China) Pharmaceuticals Co., Ltd.

Headquartered in Beijing, Novo Nordisk now employs more than 1,700 employees and has:

• regional offices in Shanghai, Guangzhou, Wuhan, Shenyang, Jinan and Hong Kong,
• production facilities in Tianjin
• a R&D center in Beijing.

Step by step, Novo Nordisk has become the leader in diabetes in China, with a complete organization covering R&D, production, sales and distribution networks.

While providing all major diabetes treatment products and comprehensive diabetes care to people with diabetes in China, Novo Nordisk is also committed to China's environment and society and has launched social programs such as for example the NovoCare Bus, the NovoCare Club and the “NovoCare Sunshine Program” in Xinjiang, which is an insulin donation program in an earthquake-ravaged area.
Type: NORMAL
Address: Unit 3112, Level 31, China World Tower 2, No. 1 Jian Guo Men Wai Avenue, Beijing 100004, China
Website: www.novonordisk.com.cn
Phone: +86-10-65058787
Fax: +86-10-65056668
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.